Healthcare & Life Sciences

A new partnership between Beacon Biosignals and Harmony Biosciences will use AI to objectively measure sleepiness, offering new hope for hypersomnia patients.

Bluerock is listing its private real estate fund on the NYSE, offering monthly payouts. Is this a game-changer for retail investors or a risky strategic play?

A familiar quit-smoking app has been rebuilt into a powerful research tool, powering Australia's largest cessation trial and setting a new standard.

Varsity Healthcare Partners' new foundation applies investment-grade rigor to its giving, funding charities with measurable health and wellness impacts.

Beyond fiber and 5G, the most vital infrastructure is human talent. A new scholarship is empowering the next generation of innovators to build it.

A new partnership claims to power an AI with meditated 'love' from at-risk communities. Is this a bold new paradigm or a controversial social experiment?

Voxel's AI transforms cameras into proactive safety systems, slashing injuries by 91% and proving that workplace safety is a powerful form of preventative care.

This new partnership is more than a sponsorship. It's a strategic move to close the gender data gap in sports science and redefine athlete care for women.

Quipt Home Medical's acquisition by private equity offers a massive premium to shareholders and sets the stage for aggressive M&A in the home respiratory care market.

As New Jersey's cannabis market booms, Grown Rogue's one-year success reveals a potent strategy for blending craft quality with low-cost execution.

A complex share buyback and reverse stock split reveal Havas's deeper strategy: shoring up its finances to invest in a new era of health communication.

A data breach at a risk management firm exposes sensitive data for thousands, raising urgent questions about industry security and accountability.

Your health plan is evolving beyond medical bills. Insurers are now funding doulas, food, and transport to tackle the root causes of poor health.

A top industrial firm offers a surprising blueprint for fixing healthcare's biggest challenges, from clinician burnout to supply chain woes.

A Chinese environmental giant and a Singaporean robotics upstart join forces. Can their automated solutions really clean up the world's dirtiest jobs?

A novel drug for alcohol use disorder gets key scientific backing. It promises the benefits of psychedelics with fewer risks, shaking up a $35B market.

After a painful restructuring, industrial manufacturer NN, Inc. is now exploring a sale. Is this the final step in its transformation or a capitulation?

PSH continues its multi-billion dollar share repurchase strategy to tackle its stubborn stock discount. What does this mean for the fund and its future targets?

Dialed Moods' new sea moss and shilajit gummies enter a booming market. But do the ancient ingredients and modern science justify the industry's latest rush?

PG&E's new grid tech does more than keep lights on; it's a vital upgrade for healthcare resilience, wildfire prevention, and safety in a changing climate.